

Private Offering · Friends & Family · Reg D 506(b) · **Confidential** · office@aetheramedical.com · aetheramedical.com

\$5.5M CAPITAL RAISE	10 CLINICS · 10 CITIES	50%→20% PROFIT SHARE → EQUITY	Month 41 BASE-CASE PAYBACK	3.8× BASE-CASE MOIC	49 MD STATE LICENSES
--------------------------------	----------------------------------	--	---	-------------------------------	--------------------------------

— The Opportunity

Regenerative medicine is projected to reach roughly **\$90B by 2030** (Grand View Research), and more than **50 million U.S. adults** live with chronic pain (CDC) — yet protocol-driven regenerative care remains fragmented single-doctor practices. No multi-city brand combines physician-led regenerative procedures, CLIA diagnostics and IRB-governed research under one roof. Aethera Medical Group is raising **\$5,500,000** to open ten integrated clinics across ten cities — five launch markets (**Boston, Miami, Nashville, Austin, Philadelphia**) with Class-A medical sites already scoped, plus five expansion markets in active site selection (Scottsdale, Los Angeles, Denver, San Diego, Chicago); avg rent across the scoped launch sites ~\$4,500/mo. Built by the operators behind RegenHealth Physicians of NY.

— The Platform — one operating system, four verticals

Every clinic runs four engines in universal, schedule-not-service treatment rooms (injections, infusions & diagnostic draws in any room — no bottleneck), with a dedicated Patient Care Coordinator per clinic driving cross-engine referrals: **Aethera Cellular Medicine** · **NeuroRenew Clinics** (Dr. Richard Miller) · **JIV Drip Bar** · **Fulcrum Performance** (Dr. Chuck Morris — flagship locations operating in NY, NJ & Dominican Republic), on a **SelfHealth** CLIA diagnostics backbone (50 states, StemAge™). Stabilized target: **\$150K/month per clinic**, anchored by a tiered membership program (Signature \$500/mo through invitation-only Aethera Private) detailed in the investor portal. Verticals: **V1** satellites (400–1,000 SF; first sites: Dr. Miller's TN & N. CA clinics, upscale hotels) · **V2** clinics (1,500–3,000 SF — this raise) · **V3** flagship wellness center (10,000–15,000 SF: hydrotherapy, performance gym, spa, bio lobby, primary care — Round 2) · **V4** online clinic (registered patients).

— Research, IP & Tax Value

IRB governance by **USMLE100** (Dr. Ali Khan — 600+ physicians trained as of July 2026, with published research; a medical professor at a Miami medical university); **RediCell x Auvum Bio** (Miami) supply regenerative biologics under USMLE100-governed protocols, enabling registered trials, publications and IP. Federal R&D credits (IRC §41) est. **\$60–200K/yr** at \$1–2M qualified spend — upside, not base case.

— Deal Structure

1) Invest \$5.5M (Reg D 506(b)). **2)** Receive **50% of net profits monthly until fully repaid** — conservative **base case** (\$150K/mo/clinic) completes by **Month 41**; the **target case** (~\$209K/mo/clinic, FDA-compliant regen + real SelfHealth revenue-share terms) completes materially faster. **3)** Retain a permanent **20% equity stake** in the parent management company (clinical services delivered through affiliated physician-owned entities where required) plus a first right of refusal on all future developments, with tax-credit and IP participation. Base case at a 10× exit: **~38% gross IRR and ~3.8× MOIC**, excluding tax/IP upside. \$200,000 is already committed; the raise deploys in milestone tranches (\$1M / \$2.5M / \$5.5M) tied to clinic openings, minimum investment \$50,000. This is a high-risk, illiquid investment; in the downside case less than half of capital returns in cash within five years, and total loss is possible.

— Use of Funds — to the dollar

buildout \$1.9M · marketing \$1.6M · Fulcrum deployment \$500K · working capital \$400K · insurance \$250K (+20% buffer) · NeuroRenew \$200K · rent deposits \$200K · credentialing \$55K (researched) · USMLE100 IRB \$100K · technology \$165K (researched) · Fulcrum IP \$100K · SelfHealth setup \$30K (researched) = **\$5,500,000**.

— Leadership (8)

Dr. Gaurav Patel MD (CMO, 49 states) · **Dr. Asif Kundi MD** (Clinical Ops, VA) · **Dr. Richard Miller DC** (NeuroRenew) · **Dr. Robert Taylor MD MPH** (Auvum Bio, Harvard) · **Jaye Patel** (Founder/BD, Harvard-HMS Stem Cell Medicine '26) · **Dr. Ali Khan MD** (USMLE100) · **Dr. Chuck Morris** (Fulcrum) · **Mihir Sharma** (CTO, VaultCyberLab).

— Ecosystem & Partners

